Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Randomized, Double-Blind, 12-Week, Placebo-Controlled Study Followed by a 12-Week Extension Phase Without Placebo to Evaluate the Efficacy and Safety of Oral VB-201 in Subjects With Mild to Moderate Ulcerative Colitis

NCT01839214 is registered in ClinicalTrials.gov with Vascular Biogenics Ltd. operating as VBL Therapeutics as lead sponsor.

NCT NCT01839214
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01839214 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Randomized, Double-Blind, 12-Week, Placebo-Controlled Study Followed by a 12-Week Extension Phase Without Placebo to Evaluate the Efficacy and Safety of Oral VB-201 in Subjects With Mild to Moderate Ulcerative Colitis
Lead sponsor
Vascular Biogenics Ltd. operating as VBL Therapeutics
Phase
Phase 2
Overall status
Completed
Start date
January 31, 2013
Completion date
November 30, 2014
Enrollment
112 (actual)
Sites
3

Conditions

As the registry lists them; a condition with its own page is linked.

ulcerative colitis